← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Intellia Therapeutics, Inc. (NTLA) 10-Year Financial Performance & Capital Metrics

NTLA •
HealthcareBiotechnologyRNA and Genome Editing Developers
AboutIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
  • Revenue $0 -100.0%
  • EBITDA $0 +100.0%
  • Net Income -$413M +20.5%
  • EPS (Diluted) -3.81 +27.4%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -53.48% +1.0%
  • ROIC -
  • Debt/Equity 0.14 -42.3%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-100%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM20.49%

EPS CAGR

10Y-
5Y-
3Y-
TTM27.43%

ROCE

10Y Avg-31.96%
5Y Avg-38.24%
3Y Avg-43.56%
Latest-

Peer Comparison

RNA and Genome Editing Developers
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ALNYAlnylam Pharmaceuticals, Inc.44.07B332.92142.8865.19%8.45%39.76%1.06%3.76
SLXNWSilexion Therapeutics Ltd.63.6M0.030.00-132.54%
EDITEditas Medicine, Inc.205.18M2.20-0.76-58.64%-430.84%-14.85%0.26
SGMOSangamo Therapeutics, Inc.92.01M0.43-0.88-67.2%-331.28%-17.44%1.34
CAMPCAMP4 Therapeutics Corporation210.49M4.49-1.6986.29%-14.04%-133.54%0.14
SLNSilence Therapeutics plc256.95M5.44-1.7170.47%-252.16%-84.61%0.00
PEPGPepGen Inc.202.89M6.22-2.18-57.35%0.16
ARCTArcturus Therapeutics Holdings Inc.224.14M8.23-2.74-12.27%-72.48%-29.71%0.12

Compare NTLA vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs ALNY

Compare head-to-head with Alnylam Pharmaceuticals, Inc.

vs IONS

Compare head-to-head with Ionis Pharmaceuticals, Inc.

Compare Top 5

vs ALNY, IONS, ARWR, CRSP

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+16.48M26.12M30.43M43.1M57.99M33.05M52.12M36.27M57.88M0
Revenue Growth %172.65%58.49%16.53%41.63%34.55%-43.01%57.69%-30.4%59.55%-100%
Cost of Goods Sold+31.84M67.65M89.11M108.41M150.41M6.89M7.57M8.98M10.29M0
COGS % of Revenue193.22%259.02%292.81%251.52%259.35%20.85%14.53%24.74%17.77%-
Gross Profit+-15.36M-41.53M-58.68M-65.31M-92.41M26.16M44.55M27.3M47.59M0
Gross Margin %-93.22%-159.02%-192.81%-151.52%-159.35%79.15%85.47%75.26%82.23%-
Gross Profit Growth %-199.67%-170.36%-41.3%-11.3%-41.5%128.31%70.28%-38.72%74.34%-100%
Operating Expenses+48.64M95.67M121.3M41.06M44.17M294.01M502.71M542.59M581.86M508.66M
OpEx % of Revenue295.15%366.32%398.58%95.26%76.16%889.52%964.51%1495.77%1005.33%-
Selling, General & Admin16.8M28.02M32.19M41.06M44.17M71.1M90.31M116.5M125.83M119.8M
SG&A % of Revenue101.94%107.31%105.77%95.26%76.16%215.1%173.26%321.15%217.41%-
Research & Development31.84M67.65M89.11M108.41M150.41M229.81M419.98M435.07M466.31M388.86M
R&D % of Revenue193.22%259.02%292.81%251.52%259.35%695.27%805.78%1199.36%805.69%-
Other Operating Expenses000-108.41M-150.41M-6.89M-7.57M-8.98M-10.29M0
Operating Income+-32.16M-69.56M-90.87M-106.37M-136.58M-267.85M-458.16M-515.29M-534.26M0
Operating Margin %-195.15%-266.32%-298.58%-246.78%-235.51%-810.37%-879.04%-1420.51%-923.1%-
Operating Income Growth %-139.83%-116.28%-30.64%-17.06%-28.41%-96.11%-71.05%-12.47%-3.68%100%
EBITDA+-31.05M-66.56M-86.41M-100.78M-130.27M-260.96M-450.59M-506.31M-523.98M0
EBITDA Margin %-188.45%-254.86%-283.91%-233.81%-224.63%-789.52%-864.51%-1395.77%-905.33%-
EBITDA Growth %-137.41%-114.33%-29.81%-16.64%-29.26%-100.32%-72.67%-12.37%-3.49%100%
D&A (Non-Cash Add-back)1.1M2.99M4.46M5.59M6.31M6.89M7.57M8.98M10.29M0
EBIT-32.16M-69.56M-90.87M-106.37M-136.58M-267.85M-458.16M-515.29M-534.26M0
Net Interest Income+525K2.01M5.53M6.83M2.35M1.28M8.54M49.83M47.81M0
Interest Income525K2.01M5.53M6.83M2.35M1.28M8.54M49.83M47.81M29.2M
Interest Expense0000000000
Other Income/Expense525K2.01M5.53M6.83M2.35M-42K-16.02M34.1M15.24M0
Pretax Income+-31.63M-67.54M-85.34M-99.53M-134.23M-267.89M-474.19M-481.19M-519.02M-412.69M
Pretax Margin %-191.97%-258.62%-280.42%-230.92%-231.46%-810.49%-909.78%-1326.51%-896.77%-
Income Tax+0000000000
Effective Tax Rate %100%100%100%100%100%100%100%100%100%100%
Net Income+-31.63M-67.54M-85.34M-99.53M-134.23M-267.89M-474.19M-481.19M-519.02M-412.69M
Net Margin %-191.97%-258.62%-280.42%-230.92%-231.46%-810.49%-909.78%-1326.51%-896.77%-
Net Income Growth %-155.17%-113.51%-26.35%-16.63%-34.86%-99.58%-77.01%-1.48%-7.86%20.49%
Net Income (Continuing)-31.63M-67.54M-85.34M-99.53M-134.23M-267.89M-474.19M-481.19M-519.02M-412.69M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.91-1.88-1.98-1.96-2.40-3.78-6.16-5.42-5.25-3.81
EPS Growth %-30%-106.59%-5.32%1.01%-22.45%-57.5%-62.96%12.01%3.14%27.43%
EPS (Basic)-0.91-1.88-1.98-1.96-2.40-3.78-6.16-5.42-5.25-3.81
Diluted Shares Outstanding34.62M36.01M43.07M47.25M55.99M70.89M76.97M88.77M98.85M108.38M
Basic Shares Outstanding34.62M36.01M43.07M47.25M55.99M70.89M76.97M88.77M98.85M108.38M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+281.31M354.83M324.98M289.48M616.52M769.3M1.22B998.33M639.86M527.71M
Cash & Short-Term Investments273.06M340.68M314.06M279.73M597.37M748.69M1.19B912.22M601.51M449.88M
Cash Only273.06M340.68M58.86M57.23M160.02M123.41M523.51M226.75M189.18M155.46M
Short-Term Investments00255.2M222.5M437.35M625.28M669.12M685.48M412.33M294.42M
Accounts Receivable6.45M10.47M7.55M4.62M2.13M2.03M3.77M36.46M8.52M9.47M
Days Sales Outstanding142.95146.3490.5139.1213.4122.4326.39366.8253.71-
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets1.79M3.68M3.37M00020.41M49.65M29.83M68.36M
Total Non-Current Assets+17.66M21.41M22.34M44.8M59.8M525.16M303.32M302.65M551.15M314.42M
Property, Plant & Equipment10.63M15.27M17.06M37.13M55.06M100.11M161M148.13M246.67M123.63M
Fixed Asset Turnover1.55x1.71x1.78x1.16x1.05x0.33x0.32x0.24x0.23x-
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments0004.75M4.75M425.05M142.32M154.51M44.26M35.54M
Other Non-Current Assets7.04M6.13M5.28M2.92M0000260.21M155.25M
Total Assets+298.97M376.24M347.31M334.28M676.32M1.29B1.52B1.3B1.19B842.13M
Asset Turnover0.06x0.07x0.09x0.13x0.09x0.03x0.03x0.03x0.05x-
Asset Growth %263.98%25.84%-7.69%-3.75%102.32%91.4%17.43%-14.42%-8.45%-29.29%
Total Current Liabilities+30.73M31.36M40.57M35.63M64.25M125.83M126.55M115.21M110.85M103.88M
Accounts Payable4.65M2.17M2.71M3.94M10.46M9.65M5.15M7.45M14.59M20.25M
Days Payables Outstanding53.3311.7211.0913.2725.38511.3248.44303.03517.74-
Short-Term Debt00000000026.48M
Deferred Revenue (Current)20.18M21.19M27.12M12.67M22.54M63.76M43.84M22.14M20.66M7.29M
Other Current Liabilities3.2M3.23M4.57M6.31M10.92M20.36M21.78M6.89M55.35M70.11M
Current Ratio9.15x11.32x8.01x8.12x9.59x6.11x9.61x8.67x5.77x5.08x
Quick Ratio9.15x11.32x8.01x8.12x9.59x6.11x9.61x8.67x5.77x5.08x
Cash Conversion Cycle----------
Total Non-Current Liabilities+58.4M44.28M28.82M28.77M85M128.39M157.98M135.6M208.21M66.85M
Long-Term Debt00000000066.85M
Capital Lease Obligations00012.63M33.61M64.91M114.02M96.75M189.95M0
Deferred Tax Liabilities0000000-38.85M00
Other Non-Current Liabilities293K168K13K00024.03M38.85M00
Total Liabilities89.13M75.64M69.39M64.4M149.25M254.22M284.53M250.81M319.06M170.73M
Total Debt+00018.38M39.3M74.02M130.7M115.35M210.2M93.33M
Net Debt-273.06M-340.68M-58.86M-38.85M-120.72M-49.38M-392.8M-111.4M21.02M-62.13M
Debt / Equity---0.07x0.07x0.07x0.11x0.11x0.24x0.14x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage----------
Total Equity+209.84M300.6M277.92M269.88M527.07M1.04B1.24B1.05B871.96M671.39M
Equity Growth %211.53%43.25%-7.54%-2.89%95.3%97.36%18.78%-15.01%-16.97%-23%
Book Value per Share6.068.356.455.719.4114.6716.0511.838.826.20
Total Shareholders' Equity209.84M300.6M277.92M269.88M527.07M1.04B1.24B1.05B871.96M671.39M
Common Stock4K4K5K5K7K7K9K9K10K12K
Retained Earnings-53.57M-121.11M-201.03M-300.88M-435.11M-703M-1.18B-1.66B-2.18B-2.59B
Treasury Stock0000000000
Accumulated OCI00-28K261K1K-2.63M-7.46M-2.26M605K1.03M
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+36.11M-65.28M-61.26M-103.24M-49.91M-225.03M-333.29M-394.09M-348.88M-348.88M
Operating CF Margin %219.12%-249.94%-201.28%-239.52%-86.06%-680.82%-639.45%-1086.38%-602.8%-
Operating CF Growth %2148.16%-280.77%6.16%-68.54%51.65%-350.85%-48.11%-18.24%11.47%0%
Net Income-31.63M-67.54M-85.34M-99.53M-134.23M-267.89M-474.19M-481.19M-519.02M-519.02M
Depreciation & Amortization1.1M2.99M4.46M5.59M6.31M6.89M7.57M8.98M10.29M10.29M
Stock-Based Compensation6.71M15.32M17.05M15.09M19.9M47.01M91.4M134.05M154.27M154.27M
Deferred Taxes-6.7M00008.93M0000
Other Non-Cash Items6.71M166K-601K-3.72M573K2.94M95.8M-3.47M-6.29M5.58M
Working Capital Changes59.91M-16.21M3.18M-20.66M57.53M-22.9M-53.87M-52.45M11.88M0
Change in Receivables-5.45M-4.02M2.92M2.93M2.49M99K-1.74M-32.69M27.94M27.94M
Change in Inventory-4.39M1.28M3.96M1.65M07.82M0000
Change in Payables1.78M-488K232K1.88M5.06M529K-4.58M2.52M6.8M6.8M
Cash from Investing+-6.17M-10.09M-260.78M25.18M-214.49M-550.78M160.31M-31.35M125.57M125.57M
Capital Expenditures-6.17M-10.09M-6.36M-6.79M-3.58M-12.76M-58.39M-13.98M-5.78M-5.78M
CapEx % of Revenue37.41%38.64%20.89%15.76%6.18%38.59%112.03%38.55%9.98%-
Acquisitions00131K-31.97M0-3M-44.68M000
Investments----------
Other Investing0-10.1K131K31.97M0044.83M0020.97M
Cash from Financing+167.3M142.98M40.22M76.43M371.78M736.69M582.96M130.32M185.75M185.75M
Debt Issued (Net)0000000000
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K0
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-3.1M1.98M11.67M4.18M13.13M43.12M17.17M10.53M8.85M185.75M
Net Change in Cash197.25M67.61M-281.82M-1.63M107.38M-39.12M409.98M-295.11M-37.57M-37.57M
Free Cash Flow+29.94M-75.37M-67.61M-110.03M-53.5M-237.79M-391.68M-408.07M-354.66M-354.66M
FCF Margin %181.71%-288.57%-222.17%-255.28%-92.25%-719.41%-751.48%-1124.94%-612.78%-
FCF Growth %793.63%-351.69%10.29%-62.74%51.38%-344.48%-64.72%-4.19%13.09%0%
FCF per Share0.87-2.09-1.57-2.33-0.96-3.35-5.09-4.60-3.59-3.27
FCF Conversion (FCF/Net Income)-1.14x0.97x0.72x1.04x0.37x0.84x0.70x0.82x0.67x0.85x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-22.82%-26.46%-29.5%-36.34%-33.69%-34.18%-41.67%-42.1%-54%-53.48%
Return on Invested Capital (ROIC)---76.16%-35.45%-32.14%-28.76%-37.48%-43.39%-43.75%-
Gross Margin-93.22%-159.02%-192.81%-151.52%-159.35%79.15%85.47%75.26%82.23%-
Net Margin-191.97%-258.62%-280.42%-230.92%-231.46%-810.49%-909.78%-1326.51%-896.77%-
Debt / Equity---0.07x0.07x0.07x0.11x0.11x0.24x0.14x
FCF Conversion-1.14x0.97x0.72x1.04x0.37x0.84x0.70x0.82x0.67x0.85x
Revenue Growth172.65%58.49%16.53%41.63%34.55%-43.01%57.69%-30.4%59.55%-100%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.